Cover Image

Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations

The objectives of this study were to describe the patterns and duration of primary and recurrent treatment in patients with ovarian cancer (OC) harboring germline BRCA1 and BRCA2 (BRCA) mutations. A retrospective review of BRCA mutation carriers with advanced, high-grade OC diagnosed between 2004 an...

Full description

Saved in:

Bibliographic Details
Main Authors:	Soledad Jorge (Author), Elizabeth M. Swisher (Author), Barbara M. Norquist (Author), Kathryn P. Pennington (Author), Heidi J. Gray (Author), Renata R. Urban (Author), Rochelle L. Garcia (Author), Kemi M. Doll (Author)
Format:	Book
Published:	Elsevier, 2019-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients
by: Yinmei Zhang, et al.
Published: (2024)

Malignant Brenner tumor associated with a germline BRCA2 mutation
by: Michael D. Toboni, et al.
Published: (2017)

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
by: Jing Nie, et al.
Published: (2023)

The occurrence of germline <it>BRCA1 </it>and <it>BRCA2 </it>sequence alterations in Slovenian population
by: Hočevar Marko, et al.
Published: (2011)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
by: Na Li, et al.
Published: (2021)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
by: Tarinee Manchana, et al.
Published: (2020)

Metastatic colorectal cancer as the primary phenotype in a hereditary breast and ovarian cancer patient with Germline BRCA1 mutation: a case report
by: Ying Liu, et al.
Published: (2022)

Contribution of germline <it>BRCA1 </it>and <it>BRCA2 </it>sequence alterations to breast cancer in Northern India
by: Sharma Veena K, et al.
Published: (2006)

Age-specific breast and ovarian cancer risks associated with germline BRCA1 or BRCA2 pathogenic variants - an Asian study of 572 familiesResearch in context
by: Weang-Kee Ho, et al.
Published: (2024)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
by: Yi Ma, et al.
Published: (2018)

Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series
by: Koji Matsuo, et al.
Published: (2018)

BRCA mutation in high grade epithelial ovarian cancers
by: Tarinee Manchana, et al.
Published: (2019)

Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
by: Kayo Inoue, et al.
Published: (2020)

BRCA1 and BRCA2 Mutations Diagnostic and Therapeutic Implications
Published: (2023)

21 Hormone replacement therapy utilization over time following risk-reducing salpingo-oophorectomy in premenopausal patients at high risk for ovarian cancer
by: Talayeh Ghezelayagh, et al.
Published: (2023)

Recurrent gynandroblastoma of the ovary with germline DICER1 mutation: A case report and review of the literature
by: Ann Marie Mercier, et al.
Published: (2021)

High rate of mutations in the BRCA1, BRCA2, CHEK2, NBN, and BLM genes in Russian ovarian cancer patients
by: Ye. I. Bateneva, et al.
Published: (2015)

Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): A review and novel case with dual germline SMARCA4 and BRCA2 mutations
by: Brooke E. Sanders, et al.
Published: (2022)

Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?
by: Sabah Alaklabi, et al.
Published: (2023)

Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations
by: Avantika Lal, et al.
Published: (2019)

Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series
by: Koji Matsuo, et al.
Published: (2015)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
by: Mauro Francesco Pio Maiorano, et al.
Published: (2023)

SMARCA4 germline gene mutation in a patient with epithelial ovarian: A case report
by: Reshma Muppala, et al.
Published: (2017)

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
by: Qin Xu, et al.
Published: (2021)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018)

Ovarian cancer arising from the proximal fallopian tube in a patient with a BRCA2 mutation
by: Nora Badiner, et al.
Published: (2021)

BRCA1 and BRCA2 Gene Mutations Screening In Sporadic Breast Cancer Patients In Kazakhstan.
by: Ainur R. Akilzhanova, et al.
Published: (2013)

The Modern Approaches and Future Perspectives on Breast and Ovarian Cancer Prevention Strategies in BRCA1 and BRCA2 Mutation Carriers: A Literature Overview
by: Sandra Sarnacka, et al.
Published: (2024)

Low-grade adenosquamous carcinoma of the breast: A case with pathogenic germline mutation in the BRIP1 gene
by: Gahie Nam, et al.
Published: (2020)

Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDO
by: Beryl L. Manning-Geist, et al.
Published: (2023)

Skin cancer risk in patients with BRCA mutations
by: Lucy J. Navsaria, MBBCh, BAO, et al.
Published: (2024)

Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
by: Chuanlin Wang, et al.
Published: (2022)

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
by: Roshni D. Kalachand, et al.
Published: (2020)

Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers
by: Alan D McCrorie, et al.
Published: (2020)

BRCA1, BRCA2 mutations - future of predictive oncology: a review of literature
by: V. N. Dmitriev, et al.
Published: (2014)

Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation
by: Natalie Shammas, et al.
Published: (2022)

Haplotype analysis suggest common founders in carriers of the recurrent <it>BRCA2 </it>mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families
by: Foulkes William D, et al.
Published: (2006)

Germline PRDM1 Variant rs2185379 in Long-Term Recurrence-Free Survivors of Advanced Ovarian Cancer
by: Mitamura T, et al.
Published: (2022)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
by: Se Ik Kim, et al.
Published: (2019)

Role of BRCA 1 и BRCA 2 gene mutations in the occurrence of male breast cancer
by: A. V. Bykova, et al.
Published: (2014)